NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Sparsentan for treating primary IgA nephropathy [ID6308]

Final Stakeholder List

Consultees	Commentators (no right to submit or appeal)
Company • Vifor Pharma (sparsentan) Patient/carer groups • Kidney Care UK • Kidney Research UK • National Kidney Federation • Polycystic Kidney Disease Charity • South Asian Health Foundation • Specialised Healthcare Alliance Healthcare professional groups • Association of Renal Industries • Association of Renal Technologists • British and Irish Hypertension Society • British Association for Nursing in Cardiovascular Care • British Association of Endocrine and Thyroid Surgeons • British Association of Urological Nurses • British Geriatrics Society • British Heart Foundation • National Metabolic Biochemistry Network • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for DGH Nephrologists • Society for Endocrinology • UK Clinical Pharmacy Association • UK Kidney Association • UK Renal Pharmacy Group	General • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Confederation • Scottish Medicines Consortium • Welsh Government • Welsh Health Specialised Services Committee Possible comparator companies • Advanz pharma (acetazolamide, amiloride hydrochloride) • AstraZeneca (dapagliflozin) • Atnahs pharma (chlortalidone, lisinopril) • Aurobindo pharma (amiloride hydrochloride, candesartan, enalapril, fosinopril, irbesartan, lisinopril, losartan, olmesartan, perindopril, ramipril, valsartan) • Boehringer Ingelheim (empagliflozin, telmisartan) • Bristol laboratories (lisinopril) • Brown & Burk (irbesartan, lisinopril, ramipril, telmisartan, losartan) • Chemidex pharma (bumetanide) • Daiichi Sankyo (olmesartan) • Dexcel pharma (enalapril, losartan)

Consultees	**Commentators (no right to submit or appeal)**
Others • Department of Health and Social Care • NHS England	• Essential pharma (amiloride hydrochloride) • Genus Pharmaceuticals Holdings Ltd [STADA] (targeted-release budesonide) • Glenmark pharma (olmesartan, perindopril, telmisartan) • Ipca laboratories (furosemide) • Martindale pharma (captopril) • Menarini Farmaceutica Internazionale SRL (canagliflozin) • Merck Sharp & Dohme (ertugliflozin) • Morningside healthcare (chlortalidone) • Mylan (bendroflumethiazide, bumetanide, candesartan, enalapril, eprosartan, indapamide, irbesartan, lisinopril, losartan, perindopril, torasemide, trandolapril, valsartan, xipamide) • Neon healthcare (candesartan) • Novartis (valsartan) • Organon Pharma (enalapril, losartan) • Pfizer (quinapril) • Pinewood healthcare (furosemide) • Rosemont pharmaceuticals (furosemide, bumetanide, lisinopril, ramipril) • Sandoz (candesartan, cyclophosphamide, losartan, perindopril, ramipril, telmisartan) • Sanofi (furosemide, irbesartan, ramipril) • Servier laboratories (indapamide, perindopril) • Sigma pharmaceuticals (indapamide) • Strides pharma (indapamide) • Takeda (azilsartan) • Ten pharma (captopril) • Thame laboratories (captopril, furosemide) • Thornton & Ross (olmesartan) • Tillomed laboratories (perindopril, amiloride hydrochloride) • Zentiva (indapamide, irbesartan, ramipril, valsartan) Relevant research groups • Cochrane Kidney and Transplant Group • Cochrane UK

Consultees	Commentators (no right to submit or appeal)
	• Genomics England • MRC Clinical Trials Unit • National Institute for Health Research • Society for Research in Rehabilitation • Wellcome Trust <u>Associated Public Health groups</u> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

<u>Consultees</u>

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement[1], respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

<u>Commentators</u>

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

[1] Non-company consultees are invited to submit statements relevant to the group they are representing.

